Cover Image
市場調查報告書

急性腎功能衰竭(ARF,急性腎障礙):開發平台分析

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213122
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
急性腎功能衰竭(ARF,急性腎障礙):開發平台分析 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 141 Pages
簡介

所謂急性腎功能衰竭(ARF),是腎臟過濾血液廢物的功能突然降低這樣的疾病。主要的症狀有睡意和呼吸急促、倦怠感、胸部疼痛,生命垂危時有痙攣和昏睡狀態等。主要的易罹病素質為,老齡化和糖尿病、高血壓、心臟衰竭、腎臟疾病等。主要的治療藥有抗生素和利尿劑等。

本報告提供全球各國治療急性腎功能衰竭(急性腎障礙)用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

急性腎功能衰竭(ARF)概要

治療藥的開發

  • 急性腎功能衰竭開發中產品:概要
  • 急性腎功能衰竭開發中產品:比較分析

各企業正在開發的急性腎功能衰竭治療藥

大學/研究機關研究中的急性腎功能衰竭治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

急性腎功能衰竭治療藥:開發中的產品一覽(各企業)

急性腎功能衰竭治療藥:研究中的產品一覽(大學/研究機關別)

急性腎功能衰竭開發治療藥的企業

  • A1M Pharma AB
  • Adrenomed AG
  • Am-Pharma B.V.
  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Cellmid Limited
  • Complexa, Inc.
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • DURECT Corporation
  • F. Hoffmann-La Roche Ltd.
  • G1 Therapeutics, Inc.
  • Ischemix, Inc.
  • kuringurufama
  • NephroGenex, Inc.
  • NeuroVive Pharmaceutical AB
  • Noorik Biopharmaceuticals AG
  • Noxxon Pharma AG
  • Nyken B.V.
  • Orion Oyj
  • ProMetic Life Sciences Inc.
  • Quark Pharmaceuticals, Inc.
  • SBI Pharmaceuticals Co., Ltd.
  • Spherium Biomed S.L.
  • STATegics, Inc.
  • Thrasos Therapeutics Inc.
  • Torrent Pharmaceuticals Limited

急性腎功能衰竭:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • (aminolevulinic acid hydrochloride + sodium ferrous citrate)
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • A1M-001
  • AB-103
  • adrecizumab
  • BB-3
  • CAB-101
  • Cardiotrophin-1
  • Cell Therapy to Activate Wnt7b for Kidney Injury
  • CMX-2043
  • CXA-10
  • cyclosporine
  • DM-199
  • DUR-928
  • HYPER-IL-6
  • KP-100IT
  • levosimendan
  • MG-53
  • MTP-131
  • N-003
  • NOXD-21
  • NYK-1341
  • PBI-4419
  • Pyridoxamine Dihydrochloride
  • QPI-1002
  • R-190
  • Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia
  • Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury
  • RLS-003
  • RO-6839328
  • Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer
  • Small Molecule to Inhibit HDAC for Acute Kidney Injury
  • SP-15016
  • STSE-15
  • THR-184
  • TRC-160334

急性腎功能衰竭治療藥:開發中產品的最新趨勢

急性腎功能衰竭治療藥:開發暫停的產品

急性腎功能衰竭治療藥:開發中止的產品

急性腎功能衰竭相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8301IDB

Summary

Global Markets Direct's, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
  • The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
  • The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Renal Failure (ARF) (Acute Kidney Injury) Overview
  • Therapeutics Development
    • Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
    • Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
    • A1M Pharma AB
    • Adrenomed AG
    • Am-Pharma B.V.
    • Angion Biomedica Corp.
    • Atox Bio Ltd.
    • Cellmid Limited
    • Complexa, Inc.
    • DiaMedica Inc.
    • Digna Biotech, S.L.
    • DURECT Corporation
    • F. Hoffmann-La Roche Ltd.
    • G1 Therapeutics, Inc.
    • Kringle Pharma, Inc.
    • NephroGenex, Inc.
    • NeuroVive Pharmaceutical AB
    • Noorik Biopharmaceuticals AG
    • Noxxon Pharma AG
    • Orion Oyj
    • ProMetic Life Sciences Inc.
    • Quark Pharmaceuticals, Inc.
    • SBI Pharmaceuticals Co., Ltd.
    • Spherium Biomed S.L.
    • STATegics, Inc.
    • Stealth BioTherapeutics Inc.
    • Thrasos Therapeutics Inc.
    • Torrent Pharmaceuticals Limited
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • A1M-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • adrecizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cardiotrophin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CXA-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DM-199 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DUR-928 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elamipretide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HYPER-IL-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KP-100IT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levosimendan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MG-53 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIX-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • N-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-4419 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pyridoxamine Dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPI-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-190 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RLS-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-6839328 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-15016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STSE-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THR-184 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRC-160334 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment
      • May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial
      • Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury
      • Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation
      • Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002
      • Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)
      • Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928
      • Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury
      • Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study
      • Nov 10, 2015: Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision
      • Nov 04, 2015: DiaMedica Provides Corporate Update
      • Nov 04, 2015: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin
      • Nov 02, 2015: Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego
      • Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials
      • Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2016
  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noxxon Pharma AG, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed S.L., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc., H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H2 2016
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2016
  • Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top